Mirabegron Aspire (Mirabegron)

Mirabegron works by selectively activating β3‑adrenergic receptors in the detrusor muscle of the bladder. This activation raises intracellular cAMP levels, causing the muscle to relax during the storage phase, thereby increasing bladder capacity and reducing involuntary contractions.

The appropriate dose of Mirabegron Aspire is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mirabegron during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Mirabegron Aspire, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class than antimuscarinic drugs. While antimuscarinics block muscarinic receptors to reduce bladder contractions, mirabegron relaxes the detrusor muscle via β3‑adrenergic activation. This distinct mechanism can provide an alternative for patients who experience antimuscarinic side effects such as dry mouth or constipation.

Mirabegron Aspire should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Mirabegron Aspire is taken orally, usually with water. The tablet is swallowed whole and should be taken at the same time each day as directed by the prescriber. Food does not significantly affect its absorption, but patients should follow any specific instructions from their healthcare provider.

Serious risks associated with mirabegron include significant hypertension, urinary retention, and rare events such as angioedema or myocardial infarction. Patients should promptly report any sudden increase in blood pressure, difficulty emptying the bladder, swelling of the face or throat, or chest pain to their clinician.

Mirabegron Aspire is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to mirabegron. Caution is also advised for individuals with moderate renal impairment or those taking strong CYP2D6 inhibitors. Healthcare providers should evaluate each patient’s medical history before initiating therapy.